Krka Underlines Message On Entering Biosimilars Arena In Europe
Slovenian Firm Open For Regulatory And Marketing Collaboration
Krka’s management discussed the firm’s latest perception of the European biosimilars market, as it reported financial results for the nine months to 30 September.
You may also be interested in...
Krka has explained a near double-digit percentage point drop for its EBITDA margin, as it presented preliminary results for the first half of 2022.
Slovenia’s Krka surprised the market with nearly 10% group turnover growth in the first quarter, driven by increases in all six of its sales regions, “most key markets, and by all product and service groups.”
Slovenian firm Krka wishes to strengthen and optimize its vertically integrated business model over the next five years, just one of many goals just published by the company under a new business plan to 2026.